This column was originally published on RealMoney on Dec. 12 at 2:01 p.m. EST. It's being republished as a bonus for TheStreet.com readers. For more information about subscribing to RealMoney, please
|Primed for Growth|
Medicis shares plummeted in June on news of the earlier-than-anticipated approval of Allergan's Juvederm. This product competes with Medicis' important Restalyne product line in the dermal-filer segment. Medicis shares have since recovered and are now about 40% above mid-summer levels, despite the coming full-scale launch of Allergan's Juvederm in January.